Mutated or deficient gene underlying the inherited metabolic disorder

The term 'Mutated or deficient gene underlying the inherited metabolic disorder' refers to the broad category of genetic defects responsible for inborn errors of metabolism (IEMs). These disorders are typically caused by mutations in genes that encode enzymes, transporters, or cofactors, leading to disrupted metabolic pathways and systemic toxicity (National Institutes of Health, 2023). Because this description encompasses a vast array of distinct genetic loci—such as those involved in amino acid, lipid, or carbohydrate metabolism—it does not represent a single, specific therapeutic target. In drug discovery, researchers focus on the specific protein product of a single gene, such as phenylalanine hydroxylase in the case of phenylketonuria (StatPearls, 2023). Therapeutic interventions for these genetic deficiencies often involve enzyme replacement therapy, substrate reduction, or emerging gene-editing technologies like CRISPR-Cas9 (PubMed, 2022). The lack of specificity in this term makes it unsuitable for standard pharmacological target classification, which requires a defined molecular entity. Consequently, while the phrase describes the underlying cause of many diseases, it serves as a placeholder for a specific gene rather than a target itself.

Other names

Inborn errors of metabolism genesMetabolic disease genesIEM-associated genes

Not applicable as this refers to a broad category of genetic defects rather than a specific molecular target.